1[1]Pisoni CN,Sanchez FJ,Karim Y,et al.Mycophenolate mofetil in systemic lupus erythematosus:efficacy and tolerability in 86 patients.J RheumatoL 2005,32:1047-1052
2[2]Walah M,James M,Jayne D,et al.Myeophenolate mofetil for induction therapy of lupus nephritis:a systematic review and metaanalysis.Clin J Am Soc Nephrol,2007,2:968-975
3[3]Zhu B,Chen N,Lin Y,et al.Myeophenolate mofetil in inductionand maintenance therapy of severe lupus nephritis:a meta-analysis of randomized controlled trials.Nephrol Dial Transplant.2007,22:1933-1942
4[4]Kasderova M,Janeova E,Rysava R,et al.Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vaaculitis and lupus nephritis.Arch Med Res,2008,39:115-119
5[5]Mok CC.Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus:a systematic review.Stand J Rheumatol.2007,36:329-337
6[6]Nilufer Yalcinda g F,Amer R,Forrester JV.Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vaseulitis.J Ocul Pharmacol Ther,2008,24:249-254
7[7]Sobrin L,Christen W,Foster CS.Myeophenolate Mofetil after Methotrexate Failure or Intolerance in the Treatment of Scleritis and Uveitis.Ophthalmology,2008,Jan 24
8[8]Liossis SN,Bounas A,Andonopoulos AP.Myeophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.Rheumatology (Oxford),2006,45:1005-1008
9[9]Willeke P,Schluter B,Beeker H,et al.Mycophenolate sodium treatment in patients with primary Sjogren syndrome:a pilot trial.Arthritis Res Ther,2007,9:R115
10[10]Herrea J,Ferrebuz A,MacGregor EG,et al.Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis.J Am Soc Nephrol,2006,17(suppl.):S218-225
2Gremillion RB, Posever JO, Manek N, et al. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patiants. J Rheumatol, 1999, 26: 2332-2336.
3Furst DE, Saag K, Fleischmann R, et al. Efficacy of tacrolimus in rheumatoid arthritis patients failing methotrexate: a six-month, double-blind, randomized, dose ranging study. Arthritis Rheum, 2002, 46: 2020-2028.
4Yocum DE, Furst DE, Bensen WG, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford), 2004, 43: 992-999.
5Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity, 1996, 5: 258-293.
6Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol, 2001, 19: 225-252.
7Mottonen M, Isomaki P, Luukkainen R, et al. Regulation of CD154-induced interleukin-12 production in synovial fluid macrophages. Arthritis Res, 2002, 4: R9.
8Skapenko A, Lipsky PE, Kraetsch HG, et al. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol, 2001, 166: 4283-4296.
9Kamradt T, Burmester GR. Cytokines and arthritis: is the Th1/ Th2 paradigm useful for understanding pathogenesis. J Rheumatol, 1998, 25: 6-8.
10Tanaka Y, Suzuki K, Saito K. Efficacy of tacrolimus for joint destruction in rheumatoid arthritis. Clin Calcium, 2007, 17: 593-599.
